Results of a Phase I/II Clinical Trial of a New Anti-Malignant Agent, AF802, for ALK-Positive Non-Small Cell Lung Cancer were Published Online on “The Lancet Oncology”
May 07, 2013
Results of a Phase I/II Clinical Trial of a New Anti-Malignant Agent, AF802, for ALK-Positive Non-Small Cell Lung Cancer were Published Online on “The Lancet Oncology”
Results of a Phase I/II Clinical Trial of a New Anti-Malignant Agent, AF802, for ALK-Positive Non-Small Cell Lung Cancer were Published Online on “The Lancet Oncology”
